U.S. Markets closed

Braxia Scientific Corp. (BRAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1800+0.0230 (+14.65%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1570
Open0.1600
BidN/A x N/A
AskN/A x N/A
Day's Range0.1563 - 0.1895
52 Week Range0.1490 - 1.2120
Volume742,351
Avg. Volume389,719
Market Cap32.313M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base

    Braxia Scientific Corp. ("Braxia Scientific," or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrie

  • CNW Group

    Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression

    Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce Braxia Scientific's clinical research and development team will commence a randomized clinical trial (RCT) using psilocybin.

  • CNW Group

    Braxia Scientific Comments on US Class Action

    Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today reported that it was served with a class action complaint against the Company, its former CEO and president, for the violation of US federal securities laws. The complaint was filed in the US District Court Central District of California and alleges that the Company and the individual defendants violated ss. 10(b) and 20(a) of the Securities and Exchange Act of 1934 and Rule 10b-5 promulga